Ally Bridge Group NY LLC lessened its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 129,291 shares of the biopharmaceutical company's stock after selling 82,500 shares during the quarter. Xenon Pharmaceuticals accounts for 4.3% of Ally Bridge Group NY LLC's portfolio, making the stock its 5th largest position. Ally Bridge Group NY LLC owned about 0.17% of Xenon Pharmaceuticals worth $5,068,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in XENE. Prudential Financial Inc. boosted its position in shares of Xenon Pharmaceuticals by 177.7% during the fourth quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company's stock valued at $1,529,000 after buying an additional 24,956 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Xenon Pharmaceuticals by 1,263.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after acquiring an additional 905,129 shares during the last quarter. Barclays PLC boosted its holdings in Xenon Pharmaceuticals by 1,275.5% during the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 13,903 shares during the period. Assenagon Asset Management S.A. grew its position in Xenon Pharmaceuticals by 12.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock valued at $9,350,000 after acquiring an additional 26,235 shares during the last quarter. Finally, Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals in the fourth quarter worth $101,000. 95.45% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price on the stock. StockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, The Goldman Sachs Group lowered their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a report on Thursday, April 17th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.78.
View Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Price Performance
Shares of NASDAQ XENE opened at $38.09 on Friday. The business has a fifty day moving average price of $34.73 and a 200 day moving average price of $38.61. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00. The stock has a market capitalization of $2.92 billion, a P/E ratio of -13.51 and a beta of 1.21.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
